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2Summary
Medicinal inorganic chemistry can exploit the unique properties of metal ions for the
design of new drugs. This has, for instance, led to the clinical application of
chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin
is, however, severely limited by its toxic side effects. This has spurred chemists to
employ different strategies in the development of new metal-based anticancer agents
with different mechanisms of action. Recent trends in the field are discussed in this
review. These include the more selected delivery and/or activation of cisplatin-related
prodrugs and the discovery of new non-covalent interactions with the classical target,
DNA. The use of the metal as scaffold rather than reactive centre and the departure
from the cisplatin paradigm of activity towards a more targeted, cancer cell-specific
approach, a major trend, are discussed as well. All this, together with the observation
that some of the new drugs are organometallic complexes, illustrates that exciting
times lie ahead for those interested in ‘metals in medicine’.
Introduction
Medicinal inorganic chemistry [1-3] is a field of increasing prominence as metal-
based compounds offer possibilities for the design of therapeutic agents not readily
available to organic compounds. The wide range of coordination numbers and
geometries, accessible redox states, thermodynamic and kinetic characteristics, and
the intrinsic properties of the cationic metal ion and ligand itself offer the medicinal
chemist a wide spectrum of reactivities that can be exploited. Although metals have
long been used for medicinal purposes in a more or less empirical fashion [4], the
3potential of metal-based anticancer agents has only been fully realised and explored
since the landmark discovery of the biological activity of cisplatin [5]. To date, this
prototypical anticancer drug remains one of the most effective chemotherapeutic
agents in clinical use. It is particularly active against testicular cancer and, if tumours
are discovered early, an impressive cure rate of nearly 100% is achieved. The clinical
use of cisplatin against this and other malignancies is, however, severely limited by
dose-limiting side-effects such as neuro-, hepato- and nephrotoxicity [5]. In addition
to the high systemic toxicity, inherent or acquired resistance is a second problem often
associated with platinum-based drugs, with further limits their clinical use. Much
effort has been devoted to the development of new platinum drugs and the elucidation
of cellular responses to them to alleviate these limitations [5,6]. These problems have
also prompted chemists to develop alternative strategies based on different metals and
aimed at different targets. We summarize here recent activities in the field of metal-
based anticancer drugs. Space limitations mean that this overview is not
comprehensive, but aims to highlight significant advances and illustrate emerging
trends.
New modes of interaction with the classical target, DNA
In classical chemotherapy, anticancer agents target DNA directly according to the
cisplatin paradigm to generate lesions which ultimately trigger cell death. Much effort
has been directed towards combatting the high systemic toxicity of traditional
platinum anticancer agents by designing drug delivery systems capable of delivering
platinum to tumour cells only.
4A recent example of the latter strategy is the encapsulation of cisplatin and carboplatin
in the hollow protein cage of the iron storage protein ferritin, which can be
internalized by some tumour tissues. Indeed, the drug-loaded protein showed
cytotoxic activity against the rat pheochromocytoma cell line (PC12) [7]. In a
different approach, minicells, bacterially-derived 400 nm anucleate particles, have
been packed with chemotherapeutics, such as cisplatin, and labelled with bispecific
antibodies. This resulted in endocytosis and ultimately drug release in cancer cells [8].
Platinum(IV) prodrugs can be used to overcome some of the problems associated with
cisplatin and its analogues [9]. The high kinetic inertness of Pt(IV) complexes relative
to their Pt(II) analogues introduces drug stability and the two extra ligands on the
octahedral metal centre offer many possibilities for modification of pharmacokinetic
parameters. As intracellular reduction of platinum(IV) to platinum(II) is usually
essential for activation and subsequent cytotoxicity, these prodrugs essentially present
better ways of delivering cisplatin (or its analogues) to the target tumour cell.
Synthetic advances now allow the inclusion of various bioactive ligands in the axial
positions, and, hence, targeting to specific types of cancer cells.
The observation that estrogen receptor-positive, ER(+), breast cancer cells treated
with estrogen are sensitized to cisplatin, led Lippard et al. to synthesize the estrogen-
tethered platinum(IV) complex 1 (see Figure 1a). Intracellular reduction releases one
equivalent of cisplatin and two equivalents of estradiol. The latter induces up-
regulation of high-mobility group (HMG) domain protein HMGB1, a protein that
shields platinated DNA from nucleotide excision repair [10].
Along a similar vein, but with the intention of overcoming platinum drug resistance
rather than cell sensitization, Dyson et al. used the Pt(IV) complex 2 (Figure 1a) to
5target cytosolic glutathione-S-transferase (GST), which constitutes the main cellular
defence against xenobiotics. Ethacraplatin (2) has the GST inhibitor ethacrynic acid, a
diuretic in clinical use, attached. Reduction of ethacraplatin in the cell results in the
release of two equivalents of a potent GST inhibitor together with one equivalent of
the cytotoxic cisplatin [11].
Lippard et al. have tackled the problem of drug delivery by attaching a Pt(IV) prodrug
to functionalized soluble single-walled carbon nanotubes (SWNT), highly effective
carriers that can transport various cargos across the cell membrane through clathrin-
dependent endocytosis [••12]. Platinum(IV) complex 3 has two different axial ligands
(Figure 1a) and binds non-covalently to the nanotube surface and one SWNT longboat
carries on average 65 platinum complexes. The conjugate shows a substantial increase
in cytotoxicity compared to the untethered complex and to cisplatin.
Sadler et al. are using a strategy that relies on the photochemical activation of
platinum(IV) drugs to release active antitumour agents, rather than spontaneous
intracellular reduction. This can then provide localized treatment of cancers accessible
to irradiation. The trans-dihydroxy platinum(IV) prodrugs are non-toxic in the dark
and incorporate two azide ligands, either positioned cis (4) [•13] or trans (5) [14] to
each other (Figure 1b). Irradiation results in growth inhibition of human bladder
cancer cells (5) and cytotoxicity towards human skin cells (HaCaT keratinocytes) (4
and 5). The discovery that the trans-isomer, a potential precursor of the inactive
transplatin, is as active as cisplatin is notable [14]. It is also notable that the cis-azide
complex is not cross-resistant to cisplatin and different DNA platination pathways
seem to be involved [•13]. Incorporation of a pyridine ligand into these complexes can
greatly increase their potency (FS Mackay et al., unpublished).
6The activity of the clinically ineffective transplatin itself is markedly enhanced upon
irradiation [15]. This, together with the observed increase in cytotoxicity upon
irradiation of dirhodium complexes [16], further illustrates the potential of
photoactivation.
A variety of ruthenium complexes have been designed which interact specifically with
the classical target, DNA [17,18]. A family of ruthenium(II)-arene complexes
developed by Sadler et al. [•19], for instance, exhibits high in vitro and in vivo
anticancer activity [20]. For example, the direct coordinative binding of the
monofunctional Ru-arene complex (6) (Figure 1c) to N7 of G bases in DNA is
complemented by intercalative binding of the biphenyl ligand and specific hydrogen
bonding interactions of the ethylenediamine NH2 groups with C6O of guanine. These
additional interactions result in unique binding modes to duplex DNA and induce
different structural distortions in DNA compared to cisplatin, which may explain why
these complexes are not cross-resistant with cisplatin [18]. Interestingly, this
chemistry has recently been extended to include osmium(II)-arene analogues, such as
7 (Figure 1c), whose hydrolytic properties can be tuned to achieve promising activity
against human A549 and A2780 ovarian cancer cells [•21].
Other ruthenium-based anticancer drugs, including the NAMI-A (9) and KP1019 (10)
drugs which are under clinical evaluation, have different modes of action and
specifically aim at non-classical targets such as gene products and cellular
transduction pathways [22]. This shift in interest, which complements the classical
approach, is one of the major trends in the field and is discussed in the later sections
of this review.
7Although much less studied than the metallodrug-DNA interactions, the interaction
of metallodrugs with protein targets and the proteome deserves more attention,
especially since such studies will not only shed light on the mechanisms of action, but
also help to identify new targets for drug therapy [17,23]. Metallodrug-protein
interactions studied by various advanced analytical techniques have been recently
reviewed [23]. Recent characterization of protein adducts of platinum and ruthenium
anticancer drugs by X-ray crystallography [24,25] or advanced mass spectrometry
[26,27] show the timeliness of this approach.
8Figure 1.
Metal-based anticancer drugs that primarily target DNA. (a) Pt(IV) complexes that
deliver cisplatin and two equivalents of estradiol (1) and the GST inhibitor ethacrynic
acid (2) after activation. (b) Photolabile platinum diazide complexes 4 and 5
demonstrate good cytotoxicity upon irradiation. (c) Typical, cytotoxic examples of the
ruthenium- and osmium-arene family of complexes.
9Non-covalent interactions with DNA
Single-stranded ends of human telomeric DNA, which consist of guanine-rich
TTAGGG repeats known to fold into G-quadruplex structures (Figure 2a), provide
interesting targets for drug design. Telomeric DNA shortens after every cell division
and after critical shortening of the telomeres, cells stop dividing and commit suicide.
Telomerase, however, maintains the length of the telomeric DNA and overexpression
of this enzyme endows the (cancer) cell with the ability to replicate indefinitely and
thus proliferate. Since telomerase accepts only the single-stranded overhang,
stabilization of the G-quadruplexes provides an attractive means of preventing
telomerase from maintaining telomere length. The Ni(II)-salphen complex (11)
(Figure 2a) incorporates the main requirements for quadruplex-stabilizing molecules,
i.e. a -delocalized system prone to stacking on a G-quartet, a positive charge that is
able to lie in the centre of the quartet, and finally, positively-charged substituents
which can interact with the grooves and loops of the quadruplex. Indeed, 11 induces a
high degree of quadruplex DNA stabilization and telomerase inhibition with telEC50
values in the range of 0.1 M [28].
An important challenge in this field is the design of complexes that bind selectively to
quadruplex over duplex DNA. Whereas the Ni(II)-salphen complex 11 shows
selectivity of > 50-fold, the manganese porphyrin 12 (Figure 2a) which follows the
same design criteria as mentioned previously, shows an exceptional 10,000-fold
selectivity for quadruplex over duplex DNA (IC50 of around 0.6 M) [•29]. These
results illustrate the potential of metal complexes as telomere-targeted
chemotherapeutics.
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Besides direct coordinative binding of metallo-agents to DNA bases, other potential
DNA binding modes include intercalation and groove binding. The latter modes are
generally non-covalent in nature.
Farrell et al. have described a discrete binding mode based on interactions that utilize
exclusively backbone functional groups [•30]. The new binding mode was observed in
the crystal structure of a double-stranded B-DNA dodecamer with TriplatinNC (13)
(Figure 2b). This trinuclear Pt(II) complex is related to the trinuclear trans-platinum
drug BBR3464, but lacks the reactive chloride ligands. TriplatinNC displays
micromolar activity against human ovarian cancer cell lines [31]. The phosphate-
selective complex binds through a multitude of specific “phosphate clamps” (see
Figure 2b), bifurcated ammine(NH)phosphate(O)amine hydrogen bonds. A series
of such phosphate clamps with one strand of DNA results in so-called “backbone
tracking”, and a combination of two interstrand clamps gives rise to (minor) “groove-
spanning”. Both interactions may be present in solution [•30].
A X-ray crystallographic study of the adduct between triple helicate [Fe2L3]4+ (Figure
2c) and palindromic DNA 5’-d(CGTACG) by Hannon, Coll et al. reveals the
metallosupramolecular helicate comfortably occupying the central hydrophobic cavity
of a three-way (Y-shaped) junction (Figure 2c) [•32]. The positive charge of the
helicate, together with the large hydrophobic surface of the aromatic rings (together
with its -stacking potential), are the driving forces behind this specific interaction.
This unprecedented mode of non-covalent DNA recognition shows that three-way
junctions, naturally occurring both in DNA and RNA, provide a new structural target
for design of novel, highly specific drugs [•32]. In principle, the palindromic sequence
allows for the formation of any oligomeric formulation through Watson-Crick
hydrogen bonding, thus presenting a dynamic combinatorial library. Addition of the
11
triple helices then drives the selective formation of the three-junction member of this
library. The DNA junction recognition compliments the previously reported major
groove binding of the iron metallohelicates, which led to remarkable intramolecular
DNA coiling [33]. The ruthenium metallohelicate induces a similar bending/coiling
effect, further illustrating that the cylinder is responsible for this effect [34]. The Ru
triple helicate exhibits cytotoxicity towards human breast cancer HBL-100 and T47D
cells, albeit with modest activity (2-5 fold less potent than cisplatin). Related
unsaturated dinuclear ruthenium double helicates, capable of classic coordinative
binding to DNA, show greatly improved cytotoxicity towards the same cell lines (30-
fold more active than cisplatin). These complexes illustrate the many possibilities of
using metallosupramolecular architectures in anticancer drug design [35].
These examples not only illustrate the role of non-covalent DNA interactions, but also
the newly-emerging trend of using the metal in a scaffold, rather than as the reactive
centre. In a highly modular approach, the use of a metal centre as a building block
allows for the spatial orientation of other functionalities (as part of the ligands), which
in turn interact favourably with the target via, for instance, hydrogen bonds
(phosphate clamps) or -stacking interactions (helicates). This trend will be discussed
in the next section.
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Figure 2.
New (non-covalent) interactions with DNA. (a) G-quadruplex binding complexes 11
and 12 show high affinity and good (11) to exceptional (12) selectivity for telomeric
DNA (centre, 1KF1.pdb). (b) The highly modular TriplatinNC (13) complex binds to
DNA via so-called ‘phosphate clamps’ (2DYW.pdb). (c) The saturated iron triple
helicate binds to a three-way DNA junction (2ET0.pdb).
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The metal as scaffold
Metals ions have been traditionally included in anticancer agents to exploit their
reactivity and have been particularly attractive because of the exceptionally wide
range of reactivities available. On the other hand, metals can also be used as building
blocks for well-defined, three-dimensional constructs. In this way, the availability of
many different coordination geometries allows for the synthesis of structures with
unique stereochemistry and orientation of organic ligands and structures which are not
accessible through purely organic, carbon-based compounds. The kinetic inertness of
the coordination/organometallic bonds make these compounds in principle behave
like organic compounds. This approach immensely expands our ability to chart
biologically-relevant chemical space [••36]. The group of Meggers has pioneered this
approach in their development of organometallic ruthenium complexes that mimic
organic enzyme inhibitors. The natural product staurosporine, for instance, is a highly
potent inhibitor for various kinases (Figure 3a). Meggers et al. replaced the
carbohydrate unit with ruthenium fragments. Structural variation by simple
substitution of the ligands on the metal to optimize the enzyme-inhibitor interactions
has resulted in the discovery of nanomolar and even picomolar protein kinase
inhibitors (Figure 3b) [37]. The co-crystal structures of Pim-1 with the organometallic
complexes nicely illustrate all salient features of these potent kinase inhibitors (Figure
3c) [38]. The relevance of these organometallic inhibitors as anticancer agents has
been demonstrated recently. They are highly cytotoxic towards human melanoma
cells. The organometallic GSK-3 inhibitor DW1/2 is a potent activator of p53 and
thus induces p53-activated apoptosis via the mitochondrial pathway in otherwise
highly chemoresistant melanoma cells [39]. The anticancer agent DW1/2 works by
14
specifically targeting a protein, rather than DNA. The development of novel drugs
with non-classical protein targets is becoming a major new theme in metal-based drug
development and will be discussed in the next section.
Figure 3.
The metal as scaffold. (a) Concept: mimicking the protein kinase inhibitor
staurosporine with an octahedral ruthenium complex. (b) DW1 (the R enantiomer of
the DW1/2 racemic mixture) activates p53 and induces apoptosis in human melanoma
cells. (c) The concept is demonstrated by the crystal structure of with the protein
kinase Pim-1. (d) The remarkably close match is illustrated by the superimposed
cocrystal structures of the organometallic inhibitor (white, 2BZI.pdb) and
staurosporine (purple, 1YHS.pdb).
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Proteins and enzymes as non-classical targets
Traditional anticancer drugs that target DNA make use of the fact that malignant cells
divide rapidly. A drawback of this strategy is that rapidly dividing healthy cells are
affected as well, causing severe toxic side-effects. Alternatively, the design of novel
agents that target cellular signalling pathways specific to cancer cells would therefore
be preferred. As genomics and proteomics have resulted in an explosion of available
information concerning the biology of cancer cells, such targeted therapies have come
within reach and offer much potential. This current shift of focus will be illustrated
with a few typical examples [17].
Human thioredoxin reductase (hTrxR) is associated with many cellular processes such
as antioxidant defence and redox homeostasis. hTrxR is found at elevated levels in
human tumour cell lines. A strong connection with the apoptosis regulator protein p53
has been established and it is strongly associated with tumour proliferation, making
hTrxR an interesting target for anticancer drugs [40]. Gold(I) complexes are amongst
the most potent inhibitors of hTrxR, a feature attributable to the high electrophilicity
of Au(I) and its preference for the selenocysteine residue of hTrxR. For example,
phosphole-gold(I) complexes (14, Figure 4a) are highly potent, nanomolar inhibitors
of hTrxR and the related human glutathione reductase (hGR) [41]. A crystal structure
of 14 with hGR shows, surprisingly, the coordinative binding of one phosphole-gold
unit to an exposed cysteine and a second gold atom that has lost both its chloride and
phosphole ligand to form a linear S-Au-S adduct at the active site (Figure 4a). IC50
values for gliobastoma cells are in the 5-15 M range.
16
This is one example from the active field of gold anticancer drugs [42], many of
which target mitochondria, increasingly recognized as a regulator of cell death.
Another promising group of gold-containing anticancer agents are the gold(III)
porphyrins (15) studied by Che et al. (Figure 4b). These complexes exhibit potent in
vitro and in vivo anticancer activity towards hepatocellular and nasopharyngeal
carcinoma [•43]. A functional proteomics study indeed suggests involvement of the
mitochondria in the induced apoptosis [•44]. Finally, gold(III) thiocarbamates are
more cytotoxic in vitro than cisplatin, including intrinsically-resistant cell lines. The
primary target is thought to be the proteasome, inhibition of which results in induction
of apoptosis [45].
Other metal-containing anticancer agents are known to target specific enzymes. The
cobalt-alkyne analogue 16 of the non-steroidal anti-inflammatory drug aspirin
(acetylsalicylic acid) (Figure 4c) exhibits high cytotoxicity in breast cancer cell lines.
The cytotoxicity correlates with cyclooxygenase (COX) inhibition. COX is involved
in eicosanoid metabolism and interference with this pathway is a promising strategy
for the development of new cytostatics [46].
Hambley et al. have explored the use of cobalt-containing compounds for the selective
inhibition of enzymes involved in the process of tumour metastasis [47]. Their
interesting strategy focuses on the selective delivery of the established maxtrix
metalloproteinase (MMP) inhibitor marimastat by complexing it to a ‘chaperone’
Co(III)-complex (17, Figure 4c). MMPs are overexpressed in tumour cells and high
levels of MMPs in cancer patients correlate with poor prognosis. The Co(III) carrier
provides an inert framework for the transportation of the inhibitor and the prodrug is
activated by a bioreduction pathway generating the more labile Co(II)-complex, which
17
leads to inhibitor release. Back-oxidation to the prodrug would be prevented by the
hypoxic nature of tumour tissue, thus achieving selective release in targeted cells
only. showed that Prodrug 17 shows significantly more growth inhibition towards
4T1.2 tumours in vivo in mice than marimastat alone, but also, unexpectedly, that both
the inhibitor and the prodrug complex potentiates metastasis [47].
Inspired by the remarkable properties of NAMI-A (9), a compound devoid of in vitro
cytotoxicity but capable of in vivo metastasis inhibition, metastasis was identified as a
primary new target [•48] and a number of other ruthenium(III) complexes have been
studied for such potential activity [•48]. Remarkably, the lead complexes of the
RAPTA family of ruthenium(II)-arene compounds (18, Figure 4d) developed by
Dyson et al. also showed the same low in vitro cytotoxicity but in vivo inhibition of
lung metastases in CBA mice bearing MCa mammary carcinoma [49].
These examples illustrate the need to develop new assays that look beyond traditional
in vitro cytotoxicity tests [22].
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Figure 4.
Proteins and enzymes as non-classical targets. This cross-section illustrates the
diversity in structure of the complexes and the many organometallic agents being
studied. (a) The Au(I)-phosphole complex 14 inhibits hTrxR. The crystal structure
shows the two gold binding sites (insets, gold atoms as orange spheres, 2AAQ.pdb).
(b) Gold(III)-porphyrin anticancer agent 15. (c) The cobalt-alkyne (16) and cobalt-
marimastat chaperone (17) complexes inhibit COX and MMP, respectively. The
cobaltocenium complex (22) carries a nuclear localization signal for directed nuclear
delivery. (d) NAMI-A (9) and the RAPTA-ruthenium complexes (18) show
antimetastatic activity. (e) Ferrocifen (19) constitutes a prototypical example of a
bioorganometallic drug. The nucleotide-appended organometallic iron complexes 20
and 21 show pronounced cytotoxicity.
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From inorganic to bioorganometallic drugs
The fact that many of the compounds mentioned above are organometallic complexes
illustrates the emergence of the field of medicinal organometallic chemistry. More
generally, bioorganometallic chemistry is relatively new, but has already led to
exciting developments [50]. A prototypical example of a promising organometallic
(pro)drug is the now well-established ferrocifen (19, Figure 4e) system. Ferrocifen, in
contrast to its parent tamoxifen, is active against both ER(+) and ER(-) human breast
cancer cell lines. The antiproliferative effect arises from the anti-estrogenic effect of
the tamoxifen-like unit combined with cytotoxicity caused by the redox properties of
the attached ferrocene group. Electrochemical studies on a variety of ferrocifen-like
compounds have revealed a structure-activity relationship and thus established
minimal structural requirements for cytotoxic effect [••51]. Organometallic iron
complexes with nucleosides appended to either a ferrocenyl [52] (21) or an 4-
butadiene-Fe(CO)3 group[53] (20) also show pronounced cytotoxic activity resulting
induction of apoptosis.
Metzler-Nolte et al. have reported the directed nuclear delivery of an organometallic
cobalt compound (22). To achieve this, the SV4-40 T antigen nuclear localization
signal (NLS) was modified with a cobaltocenium cation and other groups. These
cobaltocenium-NLS-bioconjugates present an intriguing opportunity for the targeted
delivery of therapeutics to the cell nucleus [•54].
The large diversity in recently-reported organometallic anticancer complexes,
illustrate that the full arsenal of synthetic organometallic chemistry, is now available
to the medicinal chemist. Many more exciting developments can therefore be
expected.
20
Conclusions
This survey of recent literature illustrates that many different new creative approaches
are being taken towards the design of innovative metal-based anticancer drugs. The
clinical success of cisplatin remains a stimulus for the development of new complexes
that address the downsides associated with cisplatin, especially the systemic toxicity
and (acquired) resistance. Targeted delivery and/or controlled prodrug activation, be it
by light, intracellular reduction or other means, hold the promise of more selective
and effective drug administration. The field of classical chemotherapy with DNA as
the established target continues to produce interesting discoveries. A clearly
discernible, emerging trend, however, is the departure from the cisplatin paradigm of
activity. The newly discovered, mainly non-covalent DNA interactions offer a
glimpse of the rich chemistry that remains to be discovered, most possibly with
applications reaching further than medicinal chemistry. The concept of the metal as
scaffold for the construction of unique, yet well-defined three-dimensional structures,
rather than reactive centre, holds much promise. This highly modular approach,
combined with currently available combinatorial techniques and knowledge of
supramolecular chemistry, yields a very powerful method for optimizing drug
interactions with carefully selected targets.
Future clinical success will benefit from targets which are highly specific for cancer
cells. The rapidly expanding knowledge of their cellular characteristics offers many
new opportunities for drugs that show low systemic toxicity and efficiently tackle the
problem of drug resistance. The different examples mentioned in this review offer a
promising start. Finally, the advent of medicinal bioorganometallic chemistry has
21
further expanded the toolbox of the medicinal inorganic chemist. The nature of the
research will rely ever more heavily on interdisciplinary collaboration, but many
exciting discoveries and applications almost certainly lie ahead.
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